Paper32205136
Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.
de Jong JJ and 20 others. Eur Urol Oncol, 2020. Cited by 32 papers, by iCite.
Cite this record
ConductScience Library. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Papers, record 32205136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32205136
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Expression Profiling | Major topic |
| Transcriptome | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Aged | |
| Cohort Studies | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Invasiveness | |
| Sex Characteristics |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 32444779 | Exploring the molecular basis of sexual dimorphism in bladder cancer. | https://conductscience.org/library/papers/32444779 |
Source PubMed
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42020578 | Worse bladder cancer outcomes in women than in men - bias, biology or both? | Nat Rev Urol | 2026 | https://conductscience.org/library/papers/42020578 | PubMed |
| 41463239 | Differential Androgen Receptor Expression Across Bladder Cancer Stages and Its Link to Poor Outcomes. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41463239 | PubMed |
| 40458476 | Integrative multi-omics study identifies sex-specific molecular signatures and immune modulation in bladder cancer. | Front Bioinform | 2025 | https://conductscience.org/library/papers/40458476 | PubMed |
| 39941725 | The Gender-Biased Differential Effect of KDM6A Mutation on Immune Therapy in Urothelial Carcinoma: A Public Database Study. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/39941725 | PubMed |
| 38538658 | In silico analysis of overall survival with YBX1 in male and female solid tumours. | Sci Rep | 2024 | https://conductscience.org/library/papers/38538658 | PubMed |
| 38339010 | The Urinary Microbiome in Health and Disease: Relevance for Bladder Cancer. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38339010 | PubMed |
| 37736991 | Systematic Evaluation of Imaging Features of Early Bladder Cancer Using Computed Tomography Performed before Pathologic Diagnosis. | Tomography | 2023 | https://conductscience.org/library/papers/37736991 | PubMed |
| 37604983 | The sex gap in bladder cancer survival - a missing link in bladder cancer care? | Nat Rev Urol | 2024 | https://conductscience.org/library/papers/37604983 | PubMed |
| 37131897 | Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer. | Rep Biochem Mol Biol | 2023 | https://conductscience.org/library/papers/37131897 | PubMed |
| 37096787 | Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe). | Cancer Med | 2023 | https://conductscience.org/library/papers/37096787 | PubMed |
| 37072491 | The androgen receptor in bladder cancer. | Nat Rev Urol | 2023 | https://conductscience.org/library/papers/37072491 | PubMed |
| 36964522 | Sex-biased molecular differences in lung adenocarcinoma are ethnic and smoking specific. | BMC Pulm Med | 2023 | https://conductscience.org/library/papers/36964522 | PubMed |
| 36737799 | Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. | Diagn Pathol | 2023 | https://conductscience.org/library/papers/36737799 | PubMed |
| 36325367 | Sex-specific Augmentation of Treatment Responses in Bladder Cancer. | Eur Urol Open Sci | 2022 | https://conductscience.org/library/papers/36325367 | PubMed |
| 36140470 | The Urinary Microbiome: Role in Bladder Cancer and Treatment. | Diagnostics (Basel) | 2022 | https://conductscience.org/library/papers/36140470 | PubMed |
| 35980439 | [Gender-associated differences in bladder cancer]. | Urologie | 2022 | https://conductscience.org/library/papers/35980439 | PubMed |
| 35915245 | Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. | Cancer Gene Ther | 2022 | https://conductscience.org/library/papers/35915245 | PubMed |
| 35869147 | The impact of biological sex on diseases of the urinary tract. | Mucosal Immunol | 2022 | https://conductscience.org/library/papers/35869147 | PubMed |
| 35782750 | Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer. | Ther Adv Med Oncol | 2022 | https://conductscience.org/library/papers/35782750 | PubMed |
| 35053540 | Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35053540 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32205136
GET https://conductscience.org/api/papers/v1/32205136/authors?page=2